{"title":"我们如何更好地预测经典霍奇金淋巴瘤的治疗结果?","authors":"Claudio Agostinelli","doi":"10.2217/ijh-2017-0010","DOIUrl":null,"url":null,"abstract":"“ The results indicate that response-adapted therapy based on PET-2 results guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated with ABVD. ”","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0010","citationCount":"0","resultStr":"{\"title\":\"How can we better predict treatment outcomes in classical Hodgkin's lymphoma?\",\"authors\":\"Claudio Agostinelli\",\"doi\":\"10.2217/ijh-2017-0010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"“ The results indicate that response-adapted therapy based on PET-2 results guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated with ABVD. ”\",\"PeriodicalId\":14166,\"journal\":{\"name\":\"International Journal of Hematologic Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/ijh-2017-0010\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematologic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/ijh-2017-0010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/11/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2017-0010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/11/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
How can we better predict treatment outcomes in classical Hodgkin's lymphoma?
“ The results indicate that response-adapted therapy based on PET-2 results guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated with ABVD. ”
期刊介绍:
International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.